Grufity logoGrufity logo

PACB

9.85USD-0.26(-2.57%)Delayedas of 28 Nov 2022, 11:28 am

Pacific Biosciences of California Inc

Market Summary

USD9.85-0.26Delayedas of 28 Nov 2022, 11:28 am
-2.57%

PACB Alerts

PACB Stock Price

RSI Chart

Valuation

Market Cap

2.0B

Price/Earnings

-9.53

Price/Sales

14.05

Price/Cashflow

-9.25

MarketCap/EBT

-5.46

Price/Sales

Profitability

Operating Margin

45.12%

EBT Margin

-196.98%

Return on Equity

-30.16%

Return on Assets

-10.96%

Fundamentals

Revenue

Revenue (TTM)

137.0M

Revenue Y/Y

-7.38%

Revenue Q/Q

-8.9%

Earnings

Earnings (TTM)

-299.2M

Earnings Y/Y

-565.31%

Earnings Q/Q

-7.81%

Price Action

52 Week Range

3.8523.87
(Low)(High)

Last 7 days

-4.7%

Last 30 days

14.6%

Last 90 days

69.4%

Trailing 12 Months

-56.8%

Financial Health

Current Ratio

11.5

Investor Care

Shares Dilution (1Y)

2.50%

Diluted EPS (TTM)

-1.36

Peers (Alternatives to Pacific Biosciences of California)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
14.00% 3.09%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
-7.73% -40.09%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
14.80% -4.52%
34.68
7.36
7.75% 11.02%
18.1B
2.9B
12.03% -1.70%
25.81
6.25
8.61% 6.30%
17.2B
4.6B
0.36% -22.59%
25.45
3.42
-9.73% -44.26%
MID-CAP
SMALL-CAP
2.0B
137.0M
14.63% -56.78%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
8.70% -71.21%
-4.68
6.81
19.67% -35.56%
661.5M
23.3M
-12.60% -45.72%
-6.25
28.36
76.56% -106.44%
488.2M
135.3M
-43.15% -85.19%
-3.51
3.42
-2.59% -32.75%
413.2M
110.0M
8.29% -73.27%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-6.72% -85.20%
-19.64
2.76
31.03% -107.73%
122.6M
69.0M
-6.93% -82.43%
-1.31
1.6
-18.80% -75.52%
109.5M
118.0M
- -66.15%
-29.97
0.91
0.97% -269.58%
95.7M
51.6M
-4.83% -20.62%
238.75
1.86
20.72% 150.31%

Financials for Pacific Biosciences of California

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-1.8%137140135131122
Cost Of Revenue-1.0%7677757270
Gross Profit-2.9%6162605953
Operating Expenses-0.5%345347314269223
  S&GA Expenses3.5%153148138124105
  R&D Expenses11.3%19317314511388
Earnings Before Taxes-4006.2%-274.87-6.69
Net Income-45.5%-299.19-205.68-175.29-181.22-36.96
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-3.0%1,8191,8761,9372,0072,034
  Current Assets-5.8%9149701,0291,1011,130
    Cash Equivalents-1.9%304310429461425
  Inventory20.4%4336302518
  Net PPE3.2%3938363331
  Goodwill0%410410410410412
Liabilities-0.2%1,1921,1941,2021,2161,193
  Current Liabilities-3.3%8284617256
Shareholder's Equity-8.1%627682735791841
  Retained Earnings-5.6%-1,447.96-1,370.98-1,299.59-1,218.09-1,148.76
  Additional Paid-In Capital1.1%2,0812,0582,0382,0101,989
Shares Outstanding0.5%226225224221221
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-10.6%-234.35-211.96-167.10-111.18-93.73
  Share Based Compensation-10.7%8089867360
Cashflow From Investing141.6%101-244.12-644.65-678.53-842.78
Cashflow From Financing-96.7%103073091,1701,294

Risks

What is the probability of a big loss on PACB?

100%


Probability that Pacific Biosciences of California stock will be more than 20% underwater in next one year

90%


Probability that Pacific Biosciences of California stock will be more than 30% underwater in next one year.

72.3%


Probability that Pacific Biosciences of California stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PACB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pacific Biosciences of California was unfortunately bought at previous high price.

Returns

Cumulative Returns on PACB

20.3%


10-Year Cumulative Returns

-0.4%


7-Year Cumulative Returns

27.4%


5-Year Cumulative Returns

25.5%


3-Year Cumulative Returns

What are the long-term rolling returns for PACB?

FIve years rolling returns for Pacific Biosciences of California.

Which funds bought or sold PACB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
318,000
318,000
0.01%
2022-11-22
IHT Wealth Management, LLC
ADDED
10.7
37,000
120,000
0.01%
2022-11-22
Capital Impact Advisors, LLC
NEW
-
140,000
140,000
0.14%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.85
355,000
1,583,000
-%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
1,055,000
1,055,000
-%
2022-11-18
Ambassador Advisors, LLC
UNCHANGED
-
24,000
104,000
0.03%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-7,000
-
-%
2022-11-15
STATE STREET CORP
ADDED
16.38
10,138,000
29,323,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
34.74
249,829
574,434
-%
2022-11-15
Covington Capital Management
UNCHANGED
-
7,000
29,000
-%

1–10 of 40

Latest Funds Activity

Are funds buying PACB calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own PACB

Pacific Biosciences of California News

The News Heater

Buy or Sell Pacific Biosciences of California Inc. (PACB) Stock Now | Don't Try to Be a Top Gun.2 hours ago

PACB Fair Value

Recent SEC filings of Pacific Biosciences of California

View All Filings
Date Filed Form Type Document
Nov 08, 2022
10-Q
Quarterly Report
Nov 07, 2022
8-K
Current Report
Oct 26, 2022
8-K
Current Report
Oct 03, 2022
4
Insider Trading
Sep 19, 2022
4
Insider Trading
Sep 06, 2022
3/A
Insider Trading
Aug 26, 2022
4
Insider Trading
Aug 18, 2022
4
Insider Trading
Aug 18, 2022
3
Insider Trading

Latest Insider Trading transactions for PACB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-29
Kim Susan G.
SOLD
-72,802.4
5.614
-12,968
See Remarks
2022-09-15
HENRY CHRISTIAN O
SOLD
-527,435
5.7765
-91,307
See Remarks
2022-08-25
Van Oene Mark
ACQUIRED
-
-
300,000
See Remarks
2022-08-16
Eidel Jeff
ACQUIRED
-
-
300,000
See Remarks
2022-06-10
MOHR MARSHALL
ACQUIRED
64,050
1.83
35,000
-
2022-05-18
Farmer Michele
SOLD
-19,819.4
5.547
-3,573
See Remarks
2022-03-17
Ericson William W.
ACQUIRED
-
-
1,268
-
2022-03-17
Ericson William W.
SOLD
-
-
-4,848,400
-
2022-03-02
Kim Susan G.
ACQUIRED
-
-
40,000
See Remarks
2022-03-02
HENRY CHRISTIAN O
ACQUIRED
-
-
107,500
See Remarks

1–10 of 50

Christian O. Henry
730
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 32,311$ 34,887$ 100,951$ 94,494
Cost of revenue:    
Cost of product revenue15,56815,53045,88741,449
Cost of service and other revenue3,0123,87010,61910,828
Amortization of Intangible Assets184123550123
Total cost of revenue18,76419,52357,05652,400
Gross profit13,54715,36443,89542,094
Operating expense:    
Research and development47,09227,508150,37770,323
Sales, general and administrative36,79531,606115,85186,804
Merger-related expenses 30,726 30,726
Change in fair value of contingent consideration4,280 (2,221) 
Total operating expense88,16789,840264,007187,853
Operating loss(74,620)(74,476)(220,112)(145,759)
Loss from Continuation Advances   (52,000)
Interest expense(3,664)(3,673)(11,042)(9,051)
Other income (expense), net1,313(133)1,29092
Loss before benefit from income taxes(76,971)(78,282)(229,864)(206,718)
Benefit from income taxes (94,824) (94,824)
Net (loss) income(76,971)16,542(229,864)(111,894)
Other comprehensive loss:    
Unrealized loss on investments(803)33(5,173)(58)
Comprehensive loss$ (77,774)$ 16,575$ (235,037)$ (111,952)
Net (loss) income per share:    
Diluted$ (0.34)$ 0.08$ (1.03)$ (0.56)
Basic$ (0.34)$ 0.08$ (1.03)$ (0.56)
Weighted average shares outstanding used in calculating net loss per share:    
Basic225,123202,194223,981198,545
Diluted225,123215,127223,981198,545
Product [Member]    
Revenue:    
Total revenue$ 27,509$ 30,502$ 85,928$ 82,338
Service and Other [Member]    
Revenue:    
Total revenue$ 4,802$ 4,385$ 15,023$ 12,156

PACB Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 304,433$ 460,725
Investments529,907583,675
Accounts receivable, net22,75624,241
Inventory, net43,49524,599
Prepaid expenses and other current assets13,0057,394
Short-term restricted cash300500
Total current assets913,8961,101,134
Property and equipment, net39,15432,504
Operating lease right-of-use assets, net41,53346,617
Long-term restricted cash2,9224,592
Intangible assets, net410,294410,979
Goodwill409,974409,974
Other long-term assets1,1761,170
Total assets1,818,9492,006,970
Current liabilities  
Accounts payable12,85311,002
Accrued expenses24,88636,261
Deferred revenue, current30,68910,977
Operating lease liabilities, current8,6127,710
Other liabilities, current4,6095,759
Total current liabilities81,64971,709
Deferred revenue, non-current1,76225,049
Contingent consideration liability, non-current167,496169,717
Operating lease liabilities, non-current43,16349,970
Convertible senior notes, net, non-current896,529896,067
Other liabilities, non-current1,7593,471
Total liabilities1,192,3581,215,983
Commitments and contingencies
Stockholders' equity  
Preferred stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding
Common stock, $0.001 par value: Authorized 1,000,000 shares; issued and outstanding 225,916 and 220,978 shares at September 30, 2022 and December 31, 2021, respectively226221
Additional paid-in capital2,080,5812,009,945
Accumulated other comprehensive loss(6,260)(1,087)
Accumulated deficit(1,447,956)(1,218,092)
Total stockholders' equity626,591790,987
Total liabilities and stockholders' equity$ 1,818,949$ 2,006,970